Tandem Diabetes Care Inc
Here’s what Wall Street is saying about obesity drug Wegovy following Novo Nordisk’s key study
Analysts are largely optimistic about a new class of anti-obesity medications following a landmark study released over the weekend. Novo Nordisk ‘s Select study of about 17,500 people found the use of its Wegovy decreased the risk of serious cardiovascular complications such as heart attacks. The study, which was shared at the American Heart Association […]
Read More
Obesity drugs’ popularity put a dent in these stocks. Why analysts say they’re still worth buying
Industry analysts are insisting that new weight loss and diabetes drugs like Ozempic won’t hurt the demand for insulin pumps and continuous glucose monitors, but most investors aren’t buying it. Medical device stocks have been falling session after session, prompting UBS analyst Danielle Antalffy on Wednesday to lower her price targets for Dexcom and a […]
Read More
Three stock market themes to play in the third quarter
The health care sector is often a sleepy performer but in this market turmoil it may prove to be one of the areas of not only safety in the third quarter — but growth. The third quarter could be a turbulent time, after the worst first half for stocks since 1970. As investors fear rampant […]
Read More